Navigation Links
Cardica Updates Enrollment Progress In European Clinical Trial
Date:2/27/2013

REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that 109 patients have been enrolled in the company's European clinical trial designed to evaluate the safety of its MicroCutter XCHANGE™ 30 cutting/stapling device in a variety of surgical procedures. Cardica plans to complete enrollment of 160 patients for the European clinical trial in the second calendar quarter of 2013.

"We are making progress with the MicroCutter XCHANGE 30 in Europe," said Bernard A. Hausen , M.D., Ph.D., president and chief executive officer of Cardica. "In the last four weeks, we have enrolled an additional 19 patients in our clinical trial, with more scheduled in the days ahead. And, we continue to gain valuable feedback from European surgeons deploying the device in a variety of procedures, to prepare the device for broader distribution in the near future. To date the MicroCutter XCHANGE 30 device has been used in over 280 procedures and deployed more than 800 times."

About Cardica 

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 44,100 units throughout the world. In addition, Cardica is developing the Cardica® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica® MicroC
'/>"/>

SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Neuralstem Updates ALS Stem Cell Trial Progress
10. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
11. TPI Provides Further Updates on its GMOL Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Agreement reinforces ViiV ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) today ... China of dolutegravir. The agreement will offer ... and will allow ViiV Healthcare to offer a competitive supply ... Tivicay®) for China and a number ...
(Date:7/1/2015)... , July 1, 2015 The ... group of state and regional professional rheumatology societies, ... of rheumatologists that explored perceptions of biosimilars and ... patients. Biosimilars are medicines that ... medicines. They are notably different from generic medications ...
(Date:7/1/2015)... , July 1, 2015 Jazz Pharmaceuticals plc ... be webcasting its corporate presentation at the Cantor Fitzgerald Healthcare ... Russell Cox , executive vice ... the company and a business and financial update on Wednesday, ... IST.  A live audio webcast of the ...
Breaking Medicine Technology:ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... Chinese subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired ... ("Charles River") Shanghai research facility. ...
... 24, 2011 Codexis, Inc. (Nasdaq: ... launch, its Codex® Screening Kits are in use ... pharmaceutical companies worldwide.  The announcement was made at ... here this week.   Codex® Screening ...
Cached Medicine Technology:ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/2/2015)... York (PRWEB) , ... July 02, 2015 , ... It’s no secret that what we consume can have an effect ... many people can easily feel dehydrated or perhaps even undernourished if not eating enough of the ... it can be an easy time of year to overdo it on the food front as ...
(Date:7/2/2015)... ... July 02, 2015 , ... Denver-based SlimGenics Weight Control ... was named No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz ... been recognized. The award identifies outstanding woman-owned businesses that demonstrate excellence and success ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. Jian-Dong Li, a professor ... a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a ... , The grant from the National Institute on Deafness and Other Communication Disorders ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... they will welcome four new members to their industry leading Scientific Advisory Board. ...
(Date:7/1/2015)... ... , ... Dr. Surya Challa of Chesapeake Vein Center and MedSpa in Chesapeake, ... to discuss non-invasive CoolSculpting . On the show, Dr. Challa will explain how ... reduction utilizes Cryolipolysis to literally freeze stubborn, unwanted fat away and give patients the ...
Breaking Medicine News(10 mins):Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3
... Register for ... ... -- In June of 2009, the world reached a turning point in our history. The ... result of the recent contested presidential election, demonstrations and protests ensued. The government,s crack-down on ...
... National poll finds kids in poorest families feel effects most ... taking a toll on many U.S. children, especially the poor ... their children. , The poll, conducted in the United States ... worsened in the previous six months, forcing them to spend ...
... in nonsmoking patients; could be target for treatment , ... a small molecule that might play a big part ... people who have never smoked, opening up the possibilities ... microRNA miR-21 was found particularly elevated in adenocarcinomas that ...
... ... iCRco completed its annual Asia/Pacific distributor training program in Suzhou, China, with over 60 ... ... training program in Suzhou, China, with over 60 representatives in attendance., , ,This year,s ...
... , , TIJUANA, Mexico, July 17 ... Throughout Mexico, childcare center owners are being crucified unjustly. Following a ... in Hermosillo, Sonora, the entire country has risen up in arms ... Eli Grey, whose family owns multiple centers and runs Interchildren, believes ...
... July 17 The economic downturn is impacting the health of many people ... by causing people to put off getting the health care they need. , ... offering suggestions for how to get them most for your money when it ... t put off necessary treatment , Fears about possible ...
Cached Medicine News:Health News:reThinking eHealth Webinar Announced: Hospital Marketing in the eHealth Era 2Health News:Recession Takes Toll on Children's Health 2Health News:Small Molecule Might Play Big Part in Lung Cancer 2Health News:Small Molecule Might Play Big Part in Lung Cancer 3Health News:iCRco Conducts 2009 Asia/Pacific Distributor Training Program 2Health News:iCRco Conducts 2009 Asia/Pacific Distributor Training Program 3Health News:Child Care Centers Throughout Mexico Being Crucified Unjustly, Says Interchildren, Inc. 2Health News:How to Afford Health Care in Hard Times 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: